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Genome-wide association studies (GWAS) have identified specific 
common genetic variants within a region on the long arm of 
chromosome 15 (15q25) as risk factors for lung cancer (1–3) and 
other smoking-related health outcomes, such as chronic obstruc-
tive pulmonary disease (4,5), peripheral arterial disease (3,6), low 
birth weight in offspring (7), and lower body mass index (8). This 
region contains the a5, a3, and b4 nicotinic acetylcholine receptor 
subunit gene cluster, CHRNA5-CHRNA3-CHRNB4 (CHRNA5-
A3-B4); although most studies to date have focused on the 
rs16969968 and rs1051730 single-nucleotide polymorphisms 
(SNPs) within this gene cluster, there is emerging evidence that 
other SNPs within this region are also associated with smoking 
behavior (9). A few studies have suggested that rs16969968 and 
rs1051730 SNPs do not relate to smoking history (2,10), but most 
have found them to be associated with a variety of smoking-related 
phenotypes, including tobacco dependence, heaviness of smoking 
(ie, number of cigarettes per day), risk of relapse after quitting 
smoking, age at initiation of smoking, and subjective response to 
the first cigarette smoked (1,3,7,9,11–22).
The first published study that investigated this region in rela-
tion to cigarette smoking identified the rs16969968 SNP (23), and 
this was subsequently confirmed at a genome-wide statistically 
significant threshold (24). A recent study showed that the minor 
allele of the rs16969968 missense polymorphism, D398N, in 
CHRNA5 was associated with a reduced response to a nicotinic 
agonist in vitro (25) and may therefore be the functional variant 
responsible for the association with smoking quantity. The 
rs1051730 SNP is located within the CHRNA3 gene, in a linkage 
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 Results Pooled per-allele associations showed that current smokers with one or two copies of the rs1051730–rs16969968 
risk allele had increased self-reported cigarette consumption (mean increase in unadjusted number of cigarettes 
per day per allele = 1.0 cigarette, 95% confidence interval [CI] = 0.57 to 1.43 cigarettes, P = 5.22 × 1026) and 
cotinine levels (mean increase in unadjusted cotinine levels per allele = 138.72 nmol/L, 95% CI = 97.91 to 179.53 
nmol/L, P = 2.71 × 10211). The increase in cotinine levels indicated an increased risk of lung cancer with each 
additional copy of the rs1051730–rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42).
 Conclusions Our data show a stronger association of rs1051730–rs16969968 genotype with objective measures of tobacco 
exposure compared with self-reported cigarette consumption. The association of these variants with lung cancer 
risk is likely to be mediated largely, if not wholly, via tobacco exposure.
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disequilibrium (LD) block within CHRNA5-A3-B4, and has also 
been shown to be associated with heaviness of smoking (3). This 
SNP is in perfect linkage disequilibrium with rs16969968 in sam-
ples of European ancestry (LD decay [D′] = 1.0, LD correlation 
coefficient [R2] = 1.0), and the two SNPs are commonly treated 
interchangeably (hereafter referred to as rs1051730–rs16969968). 
Across these studies, minor allele (rs1051730 T, rs16969968 A) 
carriers show increased risk of heavier smoking, as well as lung 
cancer and other health-related outcomes, compared with wild-type 
(rs1051730 C, rs16969968 G) homozygotes.
However, these studies typically rely on self-reported measures of 
smoking behavior, which do not fully capture interindividual varia-
tion in tobacco exposure (26). Two small studies have reported on 
the association of rs1051730–rs16969968 with heaviness of smoking 
among current smokers, measured by self-reported daily cigarette 
consumption and by levels of cotinine and other nicotine metabolites 
in serum (27,28). In one study, several nicotine metabolites in the 
urine were used to produce an index of nicotine equivalents (28). It 
showed that the risk alleles for lung cancer were associated with 
higher urinary nicotine equivalents among smokers, and this associ-
ation remained after adjustment for self-reported daily cigarette 
consumption. This suggests that other aspects of smoking behavior 
that influence exposure, such as depth of inhalation, are associated 
with chromosome 15 risk alleles for lung cancer.
Misreporting of smoking behavior by smokers (eg, reporting 
that they smoke fewer cigarettes than they actually do) will also 
reduce the reliability of self-reported measures as an index of expo-
sure. Therefore, the use of self-report measures of smoking behav-
ior could lead to relationships between risk alleles and disease 
outcomes such as lung cancer, apparently independently of 
smoking intensity. Consequently, this would imply a direct associ-
ation of genotype with risk of disease outcomes, when, in fact, the 
association may be entirely because of tobacco exposure. If this is 
the case, the CHRNA5-A3-B4 SNPs should be more strongly 
associated with objective measures of tobacco exposure than with 
self-report measures. This prediction is supported by another 
small genetic association study (27), which investigated serum 
cotinine levels and self-reported smoking, and showed a consider-
ably stronger association with the objective measures of exposure 
(ie, cotinine levels).
Two previous studies (27,28) that examined the association 
between CHRNA5-A3-B4 SNPs and both self-reported and objec-
tive measures of tobacco exposure were small. In this study, we 
extended this preliminary work by conducting a much larger col-
laborative investigation. We tested the association of rs1051730–
rs16969968 with both self-reported daily cigarette consumption 
and cotinine levels, which allowed us to estimate the extent to 
which the association of these SNPs with smoking behavior 
may have been underestimated, and thus the smoking-mediated 
influence of these SNPs on lung cancer and other conditions 
underappreciated.
Materials and Methods
Study Population
Data on self-reported smoking status (never smoker, former 
smoker, and current smoker), genotype (rs16969968 or rs1051730), 
and cotinine levels determined in blood (plasma or serum), as well 
as cigarette consumption (cigarettes per day) among current 
smokers, were available from participants of self-reported 
European ancestry in six independent studies (British Regional 
Heart Study [BRHS], n = 385 subjects; British Women’s Heart 
and Health Study [BWHHS], n = 400 subjects; European 
Prospective Investigation into Cancer and Nutrition [EPIC], 
n = 759 subjects; Midspan, n = 499 subjects; Patch II, n = 451 sub-
jects; Patch in Practice [PiP], n = 438 subjects) that contributed to 
this analysis (2,29–40). All studies received appropriate ethics 
approval, and informed consent was obtained from each participant. 
These studies are described in detail in Supplementary Methods 
(available online).
The data from the EPIC study were drawn from a case–control 
lung cancer study nested within the EPIC cohort. Blood and ques-
tionnaire data on self-reported smoking behavior were collected in 
a prospective manner as part of the recruitment procedure and 
before cancer diagnosis in case subjects (41). However, cotinine 
levels and self-reported cigarette consumption in current smokers 
differed between case subjects (EPIC Case) and control subjects 
(EPIC Control). Mean cotinine levels were higher in the EPIC 
CONTEXT AND CAVEATS
Prior knowledge
Two interchangeable single-nucleotide polymorphisms, rs1051730 
and rs16969968, are associated with heaviness of smoking, risk for 
lung cancer, and other smoking-related health outcomes. Previous 
studies have mostly relied on retrospective self-reported smoking 
behavior, which may have produced underestimated associations 
and masked the contribution of smoking to the observed associa-
tion of these polymorphisms with lung cancer and other health 
outcomes.
Study design
Data from six independent studies were used to assess associa-
tions of rs1051730 and rs16969968 genotype (referred to as 
rs1051730–rs16969968) with self-reported daily cigarette consump-
tion and plasma or serum cotinine levels among cigarette smokers, 
and meta-analysis of per-allele effects was conducted. The likely 
resulting association between genotype and lung cancer risk was 
also assessed.
Contribution
Associations of rs1051730–rs16969968 risk allele with increased 
self-reported cigarette consumption per day and increased cotinine 
levels were observed; however, the association with cotinine level 
was much stronger. This increase in cotinine levels indicated an 
increased risk of lung cancer (per-allele odds ratio = 1.31).
Implication
The association of rs1051730–rs16969968 genotype with lung can-
cer risk is mediated to a large extent, if not completely, by tobacco 
exposure.
Limitation
Analysis was based on current smoking status and not on lifetime 
exposure and also did not adjust for factors known to influence 
nicotine metabolism.
From the Editors
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Case subsample (1391 nmol/L, SD = 588 nmol/L) than the EPIC 
Control subsample (1006 nmol/L, SD = 589 nmol/L) even after 
adjustment for cigarette consumption (two-sided Kruskal–Wallis 
P < .001), indicating possible differences in smoking behavior 
(eg, depth of inhalation). This difference at baseline may have 
contributed to the likelihood of a subsequent lung cancer diagnosis. 
Therefore, the EPIC case subjects and control subjects were 
analyzed and presented separately in this study.
Statistical Analysis
In each contributing study, linear regression was used to calculate 
per-allele associations of rs1051730–rs16969968 genotype on daily 
cigarette consumption (cigarettes per day) and cotinine levels 
(nmol/L) in current smokers. Analyses were conducted for both 
unadjusted and adjusted for cotinine levels (in the case of associa-
tions of genotype with daily cigarette consumption) and cigarette 
consumption (in the case of associations of genotype with cotinine 
levels). In the Midspan Family Study, which is one of the Midspan 
studies (see Supplementary Methods, available online), within-
family clustering was adjusted for by including a family-level ran-
dom intercept (42). We assumed an additive model of genetic 
action, and a linear relationship between cigarette consumption 
and cotinine level, consistent with previous reports (3,43). The 
rs1051730 and rs16969968 variants are in perfect linkage disequi-
librium in HapMap3 samples of European ancestry (D′ = 1.0, R2 = 
1.0) (http://hapmap.ncbi.nlm.nih.gov/), and therefore, these in-
terchangeable SNPs were considered as a single marker in these 
analyses. These per-allele associations were pooled using a random 
effects method (44). Random effects models are typically more 
conservative than fixed-effects models, although in the absence of 
substantial between-study heterogeneity, the two methods gen-
erate similar results and generate identical results where there is 
perfect homogeneity. The I2 statistic was used to estimate the per-
centage of total variation in study estimates resulting from 
between-study heterogeneity. Conventionally, I2 values less than 
25% are considered low and unlikely to represent important hetero-
geneity (45). The Cochran Q test was used to evaluate the statis-
tical evidence for between-study heterogeneity.
To assess the congruence of our results with odds ratios (ORs) 
for lung cancer reported for rs1051730–rs16969968 genotype (1), 
data were used from a large case–control study that assessed the 
relationship between serum cotinine levels and lung cancer (46). 
This study reported odds ratios and 95% confidence intervals (CIs) 
for eight separate cotinine intervals with reference to the lowest 
cotinine range, produced using conditional logistic regression 
with adjustment for sex, year of birth, time of enrollment, and 
geographical region, and with adjustment for measurement error 
using repeated cotinine measurements on a subset of samples. 
These eight odds ratios and confidence intervals were abstracted, 
together with the midpoint of each cotinine interval, converted 
to nmol/L, with the midpoint of the highest interval taken as 
400 ng/mL as in the original report. Odds ratios and their confi-
dence intervals were logarithmically transformed so that log odds 
ratios and their standard errors were calculated. The association 
between cotinine levels and lung cancer risk is shown in 
Supplementary Figure 1 (available online). Weighted least squares 
regression was then carried out on log odds ratios, weighted by the 
inverse of the standard error squared, with the intercept forced to be 
0 to represent the odds ratio of 1 for the lowest cotinine interval. 
The resulting regression coefficient was then multiplied by the 
per-allele increase in cotinine estimated from this study and con-
verted to an expected odds ratio for lung cancer risk associated 
with each additional copy of the rs1051730–rs16969968 risk allele. 
Lower and upper limits of the confidence interval from the per-
allele increase were also calculated in the same way.
All analyses were conducted with Stata software (version 11.2; 
StataCorp, College Station TX). All statistical tests were two-sided, 
except where stated, and all P values of .05 or less were considered 
statistically significant.
Results
Characteristics of Participants
A total of 12 364 participants of self-reported European ancestry, 
with complete smoking status (including cigarette consumption 
among current smokers), cotinine levels, and genotype data, were 
available across six studies (see Table 1). Participants were classi-
fied as never smokers (n = 4771), former smokers (n = 4661), and 
current smokers (n = 2932) based on their self-reported smoking 
behavior (see Table 2).
Smoking Status, Genotype, and Cotinine Level
Cotinine levels confirmed the classification of participants as non-
smokers (ie, never smokers and former smokers) and current 
smokers (Table 2), based on conventional indicative cotinine levels 
among nonsmokers and current smokers (never smokers and former 
smokers, approximately 5 nmol/L; current smokers, >85 nmol/L) 
(47). Across all six studies, median cotinine levels for nonsmokers 
were 3.40 nmol/L or lower (ranging from 0.57 to 3.40 nmol/L), 
whereas median cotinine levels in current smokers were 968.5 
nmol/L or higher (ranging from 968.5 to 1535.0 nmol/L). As 
described previously, cotinine levels in current smokers in the 
EPIC study differed between case subjects and control subjects and 
were therefore considered separately.
Our analysis was based on current smokers to ascertain the 
relationship between rs1051730–rs16969968 genotype and both 
daily cigarette consumption and cotinine levels. Median cotinine 
levels in current smokers increased with each copy of the minor allele 
(rs1051730 T, rs16969968 A), typically by about 140 nmol/L (range 
= 45–255 nmol/L) (Table 2). Individual study associations between 
genotype and both daily cigarette consumption and cotinine levels 
are reported in Supplementary Table 1 (available online).
Association of rs1051730–rs16969968 Genotype With Daily 
Cigarette Consumption
Meta-analysis of the per-allele association of rs1051730–
rs16969968 genotype on unadjusted self-reported daily cigarette 
consumption among current smokers indicated strong evidence of 
association (Figure 1). Pooling the six studies within a random 
effects framework indicated that the risk allele was associated with 
increased self-reported cigarette consumption (mean increase in 
number of cigarettes per day per allele = 1.0 cigarette, 95% CI = 0.57 
to 1.43 cigarettes, P = 5.22 × 1026). The between-study heteroge-
neity was low and not statistically significant (I2 = 0%, Pheterogeneity = .72). 
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After adjustment for cotinine levels, the per-allele estimate was 
reduced by 50% (mean increase in number of cigarettes per day 
per allele = 0.45, 95% CI = 0.05 to 0.86 cigarettes, P = .029). 
Between-study heterogeneity remained low and was not statistically 
significant (I2 = 0%, Pheterogeneity = .51). Weak evidence for a difference 
between the estimates for the unadjusted and adjusted analyses was 
observed (P = .07) (not shown in the figure).
Association of rs1051730-rs16969968 With Cotinine Levels
Meta-analysis of the per-allele association of rs1051730–
rs16969968 genotype on unadjusted cotinine levels among current 
smokers indicated strong evidence of association (Figure 2). 
Pooling the six studies within a random effects framework indi-
cated that the risk allele was associated with increased cotinine 
levels (mean increase in cotinine levels per allele = 138.72 nmol/L, 
95% CI = 97.91 to 179.53 nmol/L, P = 2.71 × 10211). The between-
study heterogeneity was low and not statistically significant (I2 = 23%, 
Pheterogeneity = .26). Following adjustment for self-reported cigarette 
consumption, the per-allele estimate was reduced by only 18% 
(mean increase in cotinine levels per allele = 113.76 nmol/L, 95% 
CI = 76.88 to 150.64 nmol/L, P = 1.49 × 1029). Between-study 
heterogeneity remained low and was not statistically significant 
(I2 = 16%, Pheterogeneity = .31). No evidence for a difference between 
the estimates for the unadjusted and adjusted analyses was observed 
(P = .37) (not shown in the figure).
Association of rs1051730–rs16969968 Genotype With Lung 
Cancer Risk
To estimate the extent to which the association of rs1051730–
rs16969968 genotype with lung cancer is mediated via smoking, 
we applied the effect size we observed for the association with 
cotinine levels to published data on the association between cotinine 
levels and lung cancer risk. Applying weighted least squares regression 
to the log odds ratios presented by Boffetta et al. (46) produced a 
regression coefficient of 0.001945 per nmol/L of serum cotinine 
for the association between cotinine levels and lung cancer risk 
(Supplementary Figure 1, available online). Thus, the observed 
per-allele increase in cotinine levels of 138.72 nmol/L (95% 
CI = 97.91 to 179.53) would indicate an increased risk of lung 
cancer with each additional copy of the rs1051730–rs16969968 
risk allele (per-allele OR = 1.31, 95% CI = 1.21 to 1.42). This 
corresponds closely with published data for the association between 
rs1051730–rs16969968 genotype and lung cancer risk, where an 
odds ratio of 1.32 has been reported (1).
Sample Size Calculation for GWAS
We next assessed the implications of the observed stronger associ-
ation of rs1051730–rs16969968 genotype with cotinine levels, 
compared with self-reported daily cigarette consumption, for the 
design of future GWAS. The association of rs1051730–rs16969968 
with self-reported daily cigarette consumption and cotinine levels 
indicated by our results suggests that a GWAS would require 
a sample size in excess of 7000 to detect an association of the 
rs1051730–rs16969968 variant with self-reported daily cigarette 
consumption, but a sample size of only 1800–1900 to detect an 
association with cotinine levels, assuming an additive model for the 
genetic association, a minor allele frequency of 0.35, an alpha level 
of 5 × 1028, and a required power of at least 80%. In addition, a 
recall-by-genotype design, where rs1051730–rs16969968 homozy-
gotes are preselected, would require a sample size of only 200 to 
detect this association with cotinine levels, with an alpha level of 
0.05, and a required power of at least 80%.
Discussion
Our data show that rs1051730–rs16969968 genotype is strongly 
associated with tobacco exposure measured objectively via cotinine 
levels and that this association is robust even after adjustment for 
self-reported cigarette consumption. We used the per-allele asso-
ciation of genotype on cotinine levels to estimate the association 
between rs1051730–rs16969968 genotype and lung cancer risk, 
using published data on the association between cotinine levels and 
Table 1. Characteristics of participants by study*
Characteristic
Study
BRHS  
(n = 3613)
BWHHS  
(n = 3684)
EPIC Case†  
(n = 758)
EPIC Control†  
(n = 1548)
Midspan  
(n = 1872)
Patch II  
(n = 451) PiP (n = 438)
Sex, No. (%)       
 Male 3613 (100%) — 687 (64%) 948 (61%) 855 (46%) 166 (37%) 221 (51%)
 Female — 3684 (100%) 71 (36%) 600 (39%) 1017 (54%) 285 (63%) 217 (49%)
Age, mean (range), y 69 (58–81) 69 (59–80) 58 (34–78) 58 (35–79) 45 (30–59) 51 (33–73) 44 (19–78)
Genotype‡ rs1051730 rs1051730 rs1699698 rs1699698 rs1051730 rs1051730 rs1051730
Biological material Serum Serum Serum Serum Serum Plasma Plasma
* Data on genotype (rs16969968 or rs1051730), smoking status (never smoker, former smoker, and current smoker), and cotinine levels determined in blood 
(plasma or serum), as well as cigarette consumption (cigarette per day) among current smokers, in participants of European ancestry were available from six 
independent studies (BRHS = British Regional Heart Study; BWHHS = British Women’s Heart and Health Study; EPIC = European Prospective Investigation into 
Cancer and Nutrition; PiP = Patch in Practice).
† Cotinine levels and self-reported cigarette consumption differed in current smoker case subjects (EPIC Case) and control subjects (EPIC Control). Mean cotinine 
levels were higher in the EPIC Case subsample (1391 nmol/L, SD = 588) than the EPIC Control subsample (1006 nmol/L, SD = 589) even after adjustment for 
cigarette consumption (Kruskal–Wallis P < .001, two-sided), indicating possible differences in smoking behavior (eg, depth of inhalation). This difference at 
baseline may have contributed to the likelihood of a subsequent lung cancer diagnosis. Therefore, the EPIC case subjects and control subjects were analyzed  
and presented separately in this study.
‡ Genotype: rs1051730 (wild-type allele C, risk allele T); rs16969968 (wild-type allele G, risk allele A).
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lung cancer risk. Our estimate of the association between genotype 
and lung cancer risk was consistent with previously reported esti-
mates, even though we were only able to capture point prevalence 
smoking intensity (ie, based on current smoking only), and not 
lifetime exposure. These data therefore support the conclusion 
that association of rs1051730–rs16969968 genotype with lung 
cancer risk is mediated largely, if not wholly, via tobacco exposure. 
Although some studies have suggested a direct contribution of 
rs1051730–rs16969968 genotype to lung carcinogenesis, these 
have typically relied on self-report measures of smoking behavior 
which, as we have shown, do not fully capture actual exposure.
The association between these variants and lung cancer consti-
tutes Mendelian randomization evidence on the causal nature of 
the smoking–lung cancer association (48). In this case, we do not, 
of course, require such confirmation, but it serves as proof of principle 
for this approach. These findings also have important implications 
for epidemiology and genetic association studies, including large 
GWAS of cigarette smoking behavior, which typically rely on 
retrospective self-report measures. We discuss these implications 
below.
It is now well established that smokers modify their smoking 
behavior to self-titrate circulating nicotine to a level appropriate to 
their need (49). This compensatory behavior is achieved through 
varying the number of puffs, puff volume and interpuff interval, 
and covering the cigarette filter to reduce ventilation by sidestream 
air. This plasticity of smoking behavior means that estimating 
exposure to nicotine and tar in cigarette smokers is not possible 
through the use of machine protocols to calculate yield estimates 
(50) or through the simple counting of number and strength of 
cigarettes smoked. Smokers are able to titrate not only how many 
cigarettes they smoke but what strength of cigarette they smoke 
and how they smoke them. Therefore, either biochemical measures 
of exposure or naturalistic measures of smoking topography are 
necessary if an acceptable level of measurement precision is to be 
achieved (51).
By extension, GWAS that rely on self-report measures to quantify 
smoking behavior, and therefore tobacco exposure, may be insensitive 
to relatively modest genetic associations. Recent studies of smoking 
phenotypes have enjoyed considerable success in identifying loci 
associated with various aspects of smoking behavior (9,20,22). Our 
results suggest that these studies may have underestimated the 
magnitude of these associations (perhaps, in particular, in the 
case of heaviness of smoking phenotypes). It is also likely that a 
number of common variants that contribute an important pro-
portion of phenotypic variance may remain unidentified. Using 
biomarker phenotypes, such as cotinine, to assay nicotine con-
sumption and tobacco exposure may improve the success of 
GWAS and identify additional novel variants associated with 
nicotine consumption.
Our power analysis also indicates that these results have impor-
tant implications for the conduct of GWAS with respect to sample 
size. Considerably, smaller sample sizes may be sufficient to detect 
robust genome-wide associations if these use better outcome 
measures—there is a trade-off between sample size and phenotype 
Figure 1. Meta-analysis of association of 
rs1051730–rs16969968 risk allele with ciga-
rette consumption in current smokers. Data 
from six independent studies contributed to 
the meta-analysis. Cotinine levels and self-
reported cigarette consumption differed in 
current smoker case subjects (EPIC Case) 
and control subjects (EPIC Control) in the EPIC 
study, so they were analyzed separately. In 
each study, linear regression was used to 
calculate per-allele association of rs1051730–
rs16969968 genotype with daily cigarette 
consumption. Units represent cigarettes per 
day. Unadjusted and adjusted (for cotinine 
levels) analyses are shown. The I2 statistic was 
used to estimate the percentage of total 
variation in study estimates resulting from 
between-study heterogeneity. Individual study 
regression coefficients were combined using 
random effects methods. Squares represent 
per-allele regression coefficients, which rep-
resent mean increase in number of cigarettes 
per day per allele; size of the square repre-
sents inverse of the variance of the regres-
sion coefficient; horizontal lines represent 
95% CIs; diamonds represent summary esti-
mate combining the study-specific estimates 
using a random effects model; solid vertical 
line represents a regression coefficient of 0. 
P for heterogeneity was derived from the 
Cochran Q test (one-sided). All other statis-
tical tests were two-sided, and statistical 
significance required a P value of .05 or 
less. BRHS = British Regional Heart Study; 
BWHHS = British Women’s Heart and Health 
Study; CI = confidence interval; EPIC = 
European Prospective Investigation into 
Cancer and Nutrition; PiP = Patch in Practice.
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quality and/or precision. It may not always be practical or finan-
cially possible to collect such phenotypes in large samples. An 
initial GWAS based on a preliminary phenotype, which is easy to 
collect (such as cigarette consumption), can be followed up by 
high-quality/precision phenotyping (such as cotinine measure-
ments) in a sample selected by genotype on which the stored 
biological specimens are available. This combination could lead 
to considerable increases in statistical power and efficiency. In 
conventional observational epidemiology, where associations 
between self-reported smoking behavior and outcomes underesti-
mate the actual etiological associations that exist (52), more 
detailed phenotyping reveals stronger associations (46). Residual 
associations between other exposures and smoking-related out-
comes, such as lung cancer, which persist after statistical control 
for self-reported cigarette consumption, should therefore be treated 
with caution (53).
There are some limitations to consider when interpreting these 
results. First, our data are drawn from disparate studies recruited 
from various populations. Nevertheless, the consistency in effect 
size estimates across samples, and the lack of substantial between-
study heterogeneity, suggests that the impact of this is minimal. 
Second, our estimate of the strength of the association between 
genotype and cotinine exposure on lung cancer risk relies on an 
indirect comparison with published data. Moreover, it relies on 
measures of current smoking rather than lifetime exposure, which 
is more strongly associated with lung cancer risk. Nevertheless, the 
triangulation of our data with published estimates of the association 
of genotype with lung cancer risk raises confidence in these results. 
Third, we lacked repeated measurement of cotinine, which would 
allow the assessment of within- and between-person variation 
(eg, due time between last cigarette smoked and collection of 
biological sample for cotinine analysis), and the time of day that 
cotinine samples were collected was not standardized, either 
within or between samples. However, the relatively long half-life 
of cotinine means it provides a reasonably stable measure of expo-
sure in regular cigarette smokers. Also, the lack of substantial 
between-study heterogeneity again suggests that the impact of 
this was modest. Fourth, we were unable to capture interindi-
vidual variation in cotinine metabolism, for example due to 
genetic variation within cytochrome P450, family 2, subfamily A, 
polypeptide 6 (CYP2A6), which encodes the CYP2A6 enzyme 
primarily responsible for the metabolism of nicotine to cotinine 
(54). Therefore, although cotinine levels provide a considerably 
more precise measure of tobacco exposure than self-report 
measures, including measures of CYP2A6 activity might serve to 
refine this further. It is also possible that increased nicotine con-
sumption among rs1051730–rs16969968 risk allele carriers may 
result in CYP2A6 enzyme induction, giving rise to a positive feed-
back cycle as faster metabolism of nicotine leads to increased 
consumption to maintain circulating levels (55). However, evi-
dence suggests that nicotine metabolism is inhibited in smokers 
compared with nonsmokers (56). We also did not adjust for other 
factors known to influence nicotine metabolism, such as sex and 
body mass index.
Figure 2. Meta-analysis of association of 
rs1051730–rs16969968 risk allele with coti-
nine levels in current smokers. Data from six 
independent studies contributed to the 
meta-analysis. Cotinine levels and self-
reported cigarette consumption differed in 
current smoker case subjects (EPIC Case) 
and control subjects (EPIC Control) in the 
EPIC study, so they were analyzed sepa-
rately. In each study, linear regression 
was used to calculate per-allele association 
of rs1051730–rs16969968 genotype with 
cotinine levels. Units represent nmol/L. 
Unadjusted and adjusted (for cigarette con-
sumption) analyses are shown. The I2 statis-
tic was used to estimate the percentage of 
total variation in study estimates resulting 
from between-study heterogeneity. 
Individual study regression coefficients were 
combined using random effects methods. 
Squares represent per allele regression coef-
ficient, which represents mean increase in 
cotinine levels per allele; size of the square 
represents inverse of the variance of the 
regression coefficient; horizontal lines repre-
sent 95% CIs; diamonds represent summary 
estimate combining the study-specific esti-
mates with a random effects model; solid 
vertical line represents a regression coeffi-
cient of 0. P for heterogeneity was derived 
from the Cochran Q test (one-sided). All 
other statistical tests were two-sided, and 
statistical significance required a P value of 
.05 or less. BRHS = British Regional Heart 
Study; BWHHS = British Women’s Heart and 
Health Study; CI = confidence interval; EPIC = 
European Prospective Investigation into 
Cancer and Nutrition; PiP = Patch in Practice.
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In conclusion, our data indicate that much of the debate 
regarding whether the association of rs1051730–rs16969968 
genotype with lung cancer is direct or operate indirectly via 
tobacco exposure is essentially due to imprecision in the measures 
of tobacco use and exposure used in most studies. More impor-
tantly, our results show that the search for even larger sample sizes 
in GWAS may generate diminishing returns if this is at the 
expense of phenotype precision. The use of objective measures of 
smoking behavior in genome-wide studies may reveal novel vari-
ants associated with these outcomes, which would be undetectable 
using conventional self-report measures.
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